Evaluation of a new antipsychotic agent. Piperacetazine (quide).
D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000139:chemically induced; D000932:Antiemetics; D005260:Female; D006634:Histamine H1 Antagonists; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007565:Jaundice / Q000139:chemically induced; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D010640:Phenothiazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012640:Seizures / Q000139:chemically induced; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000932:Antiemetics; D006634:Histamine H1 Antagonists; D007659:Ketones; D010640:Phenothiazines; D014149:Tranquilizing Agents